Advertisement
Screener

Cellectar Biosciences, Inc. (CLRB) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

Cellectar Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 1.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-04

  • Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-03-31 was 107.00%.
  • Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2013-09-30 was 109.00%, a 5.22% decline year-over-year.
  • Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2013-03-31 was 109.00%.
  • Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2012-09-30 was 115.00%.
  • Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 1.00%, a 21.97% increase from fiscal 2024.
  • Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 0.82%.
  • Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2013 was 109.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2025-12-311.00%
10-K · filed 2026-03-04
2024-12-310.82%
10-K · filed 2025-03-13
2016-06-30109.00%
10-Q · filed 2016-08-11
2015-03-31107.00%
10-Q · filed 2015-05-20
2014-09-30108.00%
10-Q · filed 2015-11-12
2014-06-30108.00%
10-Q · filed 2015-08-12
2013-12-31109.00%
10-K · filed 2015-05-20
2013-09-30109.00%
10-Q · filed 2013-11-13
109.00%
10-Q · filed 2015-05-20
2013-06-30109.00%
10-Q · filed 2014-08-04
2013-03-31109.00%
10-Q · filed 2014-05-14
2012-09-30115.00%
10-Q · filed 2013-11-13
115.00%
10-Q · filed 2013-11-13
2011-09-30110.00%
10-Q · filed 2012-11-06
2011-06-30110.00%
10-Q · filed 2012-08-09
110.00%
10-Q · filed 2012-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Lipocine Inc. (LPCN)United States$0.017B-1.79
Cocrystal Pharma, Inc. (COCP)United States$0.022B
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66